Macrogen Past Earnings Performance
Past criteria checks 0/6
Macrogen's earnings have been declining at an average annual rate of -67.3%, while the Life Sciences industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 5.6% per year.
Key information
-67.3%
Earnings growth rate
-67.2%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 5.6% |
| Return on equity | -14.6% |
| Net Margin | -16.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Macrogen, Inc.'s (KOSDAQ:038290) Low P/S No Reason For Excitement
Nov 13
Macrogen, Inc.'s (KOSDAQ:038290) Revenues Are Not Doing Enough For Some Investors
Jul 24Macrogen's (KOSDAQ:038290) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 02Macrogen (KOSDAQ:038290) Has Debt But No Earnings; Should You Worry?
Mar 03Reflecting on Macrogen's (KOSDAQ:038290) Share Price Returns Over The Last Three Years
Jan 09
Revenue & Expenses Breakdown
How Macrogen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 131,729 | -21,730 | 44,553 | 4,546 |
| 30 Jun 24 | 131,018 | -20,526 | 43,936 | 4,546 |
| 31 Mar 24 | 131,009 | -20,395 | 43,198 | 4,546 |
| 31 Dec 23 | 132,803 | -16,814 | 40,798 | 4,546 |
| 30 Sep 23 | 133,923 | -22,286 | 40,977 | 4,267 |
| 30 Jun 23 | 137,180 | -18,778 | 41,351 | 4,267 |
| 31 Mar 23 | 136,765 | -20,892 | 40,563 | 4,267 |
| 31 Dec 22 | 138,617 | -22,253 | 40,089 | 4,267 |
| 30 Sep 22 | 137,850 | 2,257 | 41,523 | 4,101 |
| 30 Jun 22 | 130,775 | 872 | 37,414 | 4,101 |
| 31 Mar 22 | 130,268 | 4,212 | 34,887 | 4,101 |
| 31 Dec 21 | 129,175 | 1,112 | 32,633 | 4,101 |
| 30 Sep 21 | 125,233 | -12,321 | 27,417 | 6,244 |
| 30 Jun 21 | 123,962 | 1,299 | 26,096 | 6,244 |
| 31 Mar 21 | 118,037 | 213 | 25,653 | 6,244 |
| 31 Dec 20 | 112,603 | 4,267 | 26,022 | 6,244 |
| 30 Sep 20 | 95,787 | 19,627 | 21,933 | 6,183 |
| 30 Jun 20 | 98,483 | 4,341 | 23,953 | 6,183 |
| 31 Mar 20 | 101,852 | 10,527 | 23,596 | 6,183 |
| 31 Dec 19 | 102,815 | 17,892 | 23,425 | 6,183 |
| 30 Sep 19 | 120,208 | 12,059 | 26,810 | 6,679 |
| 30 Jun 19 | 115,150 | 12,488 | 25,808 | 6,679 |
| 31 Mar 19 | 115,639 | 9,104 | 26,369 | 6,679 |
| 31 Dec 18 | 112,831 | 2,645 | 25,341 | 6,679 |
| 30 Sep 18 | 108,575 | 12,550 | 26,592 | 5,188 |
| 30 Jun 18 | 107,959 | 13,228 | 24,914 | 5,188 |
| 31 Mar 18 | 104,462 | 14,173 | 24,457 | 5,188 |
| 31 Dec 17 | 101,793 | 9,529 | 23,620 | 5,188 |
| 30 Sep 17 | 98,472 | 1,661 | 23,116 | 4,930 |
| 30 Jun 17 | 94,772 | -558 | 21,662 | 4,930 |
| 31 Mar 17 | 92,395 | 6 | 20,836 | 4,930 |
| 31 Dec 16 | 91,113 | 4,301 | 20,081 | 4,930 |
| 30 Sep 16 | 88,207 | 7,049 | 17,691 | 4,178 |
| 30 Jun 16 | 90,663 | 11,895 | 17,877 | 4,178 |
| 31 Mar 16 | 87,030 | 11,508 | 16,777 | 4,178 |
| 31 Dec 15 | 79,534 | 10,172 | 16,522 | 4,178 |
| 30 Sep 15 | 73,926 | 4,746 | 18,482 | 3,385 |
| 30 Jun 15 | 63,116 | 2,812 | 17,152 | 3,385 |
| 31 Mar 15 | 58,090 | 2,435 | 16,348 | 3,385 |
| 31 Dec 14 | 54,130 | 2,989 | 14,313 | 3,385 |
| 30 Sep 14 | 50,107 | 5,431 | 18,197 | 390 |
| 30 Jun 14 | 48,688 | 5,641 | 16,671 | 1,117 |
| 31 Mar 14 | 48,437 | 6,437 | 15,123 | 1,936 |
| 31 Dec 13 | 48,078 | 6,426 | 14,625 | 2,588 |
Quality Earnings: A038290 is currently unprofitable.
Growing Profit Margin: A038290 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A038290 is unprofitable, and losses have increased over the past 5 years at a rate of 67.3% per year.
Accelerating Growth: Unable to compare A038290's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A038290 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (12.3%).
Return on Equity
High ROE: A038290 has a negative Return on Equity (-14.61%), as it is currently unprofitable.